Effectiveness of Etanercept in Rheumatoid Arthritis: Real-World Data from the German Non-interventional Study ADEQUATE with Focus on Treat-to-Target and Patient-Reported Outcomes

Autor: Eugen Feist, Xenofon Baraliakos, Frank Behrens, Diamant Thaçi, Thilo Klopsch, Anja Plenske, Lisa K. Blindzellner, Pascal Klaus, Thomas Meng, Peter-Andreas Löschmann
Jazyk: angličtina
Rok vydání: 2022
Předmět:
Zdroj: Rheumatology and Therapy, Vol 9, Iss 2, Pp 621-635 (2022)
Druh dokumentu: article
ISSN: 2198-6576
2198-6584
DOI: 10.1007/s40744-021-00418-5
Popis: Abstract Background For rheumatoid arthritis (RA), the treat-to-target concept suggests attaining remission or at least low disease activity (LDA) after 12 weeks. Objectives This German, prospective, multicenter, non-interventional study aimed to determine the proportion of patients with RA who achieved their treat-to-target aim after 12 and 24 weeks of etanercept (ETN) treatment in a real-life setting, as opposed to patients achieving their therapeutic target at a later timepoint (week 36 or 52). Methods A total of 824 adults with a confirmed diagnosis of RA without prior ETN treatment were included. Remission and LDA were defined as DAS28
Databáze: Directory of Open Access Journals
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje